Immuno-Oncology – Market Analysis, Trends, Opportunities and Unmet Needs – Thematic Research
Immuno-oncology (IO) refers to the development of therapies that utilize the human body’s immune responses, both adaptive and innate, to target cancer. The total market size for the five classes of immuno-oncology agents was $29 billion in 2019.
The immuno-oncology thematic research report gives an overview of key marketed and pipeline immuno-oncology drugs including classification of therapy and technologies, regulatory and market access details, product & company profiles. It analyses the key dynamics of the IO market and provides the key industry drivers and challenges.
Immuno-Oncology Market Value by Class
To know more about the immuno-oncology market forecast, download a free report sample
Immuno-Oncology: Trends and Opportunities
The bispecific antibody field has generated a lot of excitement in oncology and physicians believe there will be multiple products approved in the coming years. So far, bispecific antibodies have offered new options when traditional IO therapies such as checkpoint modulation fail. New efforts to change the tumor microenvironment are viewed as promising to combat resistance to IO therapies.
The tolerability of peptide vaccines makes them excellent candidates for use in the adjuvant setting to promote more long-term responses and reduce the risk of tumor recurrence. Vaccines score very highly in the potential for combinations, particularly with immune checkpoint inhibitors. Straightforward administration for non-personalized vaccines allows rapid integration into current standards of care. Developers can capitalize on the success of COVID-19 mRNA vaccines to revive the mRNA cancer vaccine field.
Immuno-Oncology: Value Chain Analysis
The immuno-oncology value chain consists of bispecific antibodies, oncolytic viruses, and cell therapies.
Bispecific Antibodies: They aim to bring two different cell or protein types into proximity to promote some biological function. Bispecific T-cell engagers are especially relevant to IO. The current leader in the bispecific antibody segment of immuno-oncology is Amgen, which is the only company in oncology with an FDA-approved bispecific antibody (Blincyto).
Immuno-Oncology Value Chain Analysis
For more insights on the Immuno-Oncology value chain, download a free report sample
Marketed Immuno-Oncology Products in the 7MM by Types
Bispecific antibodies, cancer vaccines, cell therapies, checkpoint modulators, and oncolytic viruses are the key types of marketed immuno-oncology products in the 7MM. Cancer vaccines lead the category in the number of marketed IO products, followed by checkpoint modulators.
Marketed Immuno-Oncology Products Analysis by Types
For more insights on the types of marketed immuno-oncology products, download a free report sample
Marketed Immuno-Oncology Products in the 7MM by Therapy Areas
Metastatic melanoma, non-small cell lung cancer (NSCLC), small-cell lung cancer, hepatocellular carcinoma, and metastatic transitional (urothelial) tract cancer are some of the key therapy areas in the marketed immuno-oncology products in the 7MM. Metastatic melanoma and NSCLC have the majority number of marketed products.
Marketed Immuno-Oncology Products Analysis by Therapy Areas
For more insights on the marketed immuno-oncology products by therapy areas, download a free report sample
Immuno-Oncology Pipeline Products in the 7MM by Types
Bispecific antibodies, cancer vaccines, cell therapies, checkpoint modulators, and oncolytic viruses are the key types of immuno-oncology pipeline products. Cell therapies have the maximum number of pipeline products, followed by cancer vaccines.
Immuno-Oncology Pipeline Products Analysis by Types
For more insights on the immuno-oncology pipeline products by types, download a free report sample
Immuno-Oncology Pipeline Products in the 7MM by Therapy Areas
Non-small cell lung cancer (NSCLC), gastric cancer, hepatocellular carcinoma, metastatic melanoma, and various solid tumors are some of the key therapy areas in the immuno-oncology pipeline products. NSCLC has the majority number of pipeline products, followed by various solid tumors.
Immuno-Oncology Pipeline Products Analysis by Therapy Areas
For more insights on the immuno-oncology pipeline products by therapy areas, download a free report sample
Immuno-Oncology Market – Leading Companies
Some of the leading companies making their mark within the immuno-oncology theme are Novartis Merck & Co., Gilead Sciences, Roche, Bristol Myers Squibb, AstraZeneca, IQVIA, and Sanofi among others.
Novartis: Headquartered in Basel, Switzerland, Novartis is a healthcare company that focuses on the discovery, development, manufacture, and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company operates through a network of subsidiaries and offices in the Americas, Europe, the Middle East, Africa, and Asia Pacific.
Merck & Co Inc: Merck is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines, biologic therapies, vaccines, and animal health products. It offers prescription products for treating cardiovascular, infectious, respiratory, and women’s diseases, cancer, immune disorders, and diabetes.
Immuno-Oncology Report Overview
| Report Pages | 146 |
| Regions Covered | Global |
| Key Trends | Industry Trends, and Regulatory Trends |
| Value Chain | Bispecific Antibodies, Oncolytic Viruses, and Cell Therapies |
| Key Types (Marketed Products) | Bispecific Antibodies, Cancer Vaccines, Cell Therapies, Checkpoint Modulators, and Oncolytic Viruses |
| Key Therapy Areas (Marketed Products) | Metastatic Melanoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Hepatocellular Carcinoma, and Metastatic Transitional (Urothelial) Tract Cancer |
| Key Types (Pipeline Products) | Bispecific Antibodies, Cancer Vaccines, Cell Therapies, Checkpoint Modulators, and Oncolytic Viruses |
| Key Therapy Areas (Pipeline Products) | Non-Small Cell Lung Cancer, Gastric Cancer, Hepatocellular Carcinoma, Metastatic Melanoma, and Various Solid Tumors |
| Leading Companies | Novartis Merck & Co., Gilead Sciences, Roche, Bristol Myers Squibb, AstraZeneca, IQVIA, and Sanofi |
Scope:
- Overview of immuno-oncology including classification of therapy and technologies, regulatory and market access details, product & company profiles.
- Quotes from US- and 5EU-based key opinion leaders and payers.
- Key topics covered for IO in the 7MM include trends, value chain, market analysis, opportunities, challenges and unmet needs and high-value deals.
- Pipeline analysis: Comprehensive data split across different phases and indications, emerging novel trends under development, and analysis of the most promising late-stage pipeline drugs for each class of IO (Phase II – III).
- Analysis of the key dynamics of the IO market. Insightful review of the key industry drivers and challenges. Deals and R&D strategies covered in detail to highlight business opportunities.
- Robust analysis of high-prescriber survey conducted with 80 oncologists.
- Components of the report include primary and secondary research:
- Quotes from key opinion leaders and payers
- Summary of immuno-oncology definitions and classifications
- Overview of key marketed and pipeline immuno-oncology drugs, including bispecific antibodies, cancer vaccines, cell therapies, checkpoint modulators and oncolytic viruses
- Trends in the immuno-oncology drug market
- Call-outs of key information and details
- Insight from GlobalData’s specialist healthcare analysts
Key Questions Answered:
- What impact will late-stage pipeline agents have on the market? Which class of IO drugs will have the highest peak sales, and why?
- What are the current unmet needs in IO, which pipeline agents or strategies are positioned to counter these unmet needs? What are the opportunities for R&D?
- How is the field of checkpoint modulation going to move forward? Which technologies are the most promising for combinations?
- What is the regulatory landscape for IO agents in the US, the 5EU and Japan?
- What is the current and future outlook of IO according to high prescribers?
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current deals and technologies to identify companies with the highest potential.
- Develop business strategies by understanding the trends shaping and driving the global immuno-oncology therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global immuno-oncology market in the future.
- Design your development strategy through a review of potential novel targets or combinations across indications.
- Understand the challenges and strategies impacting the development of immuno-oncology agents in preclinical studies and clinical trials.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the classes of IO and indications that present maximum opportunities for consolidations, investments and strategic partnerships.
Key Players
Table of Contents
Frequently Asked Questions
GlobalData’s immuno-oncology value chain is split into three segments: bispecific antibodies, oncolytic viruses, and cell therapies.
Bispecific antibodies, cancer vaccines, cell therapies, checkpoint modulators, and oncolytic viruses are the key types of marketed immuno-oncology products in the 7MM.
Metastatic melanoma, non-small cell lung cancer, small-cell lung cancer, hepatocellular carcinoma, and metastatic transitional (urothelial) tract cancer are some of the leading therapy areas in the marketed immuno-oncology products in the 7MM.
Bispecific antibodies, cancer vaccines, cell therapies, checkpoint modulators, and oncolytic viruses are the key types of immuno-oncology pipeline products in the 7MM.
Non-small cell lung cancer, gastric cancer, hepatocellular carcinoma, metastatic melanoma, and various solid tumors are some of the leading therapy areas in the immuno-oncology pipeline products in the 7MM.
Some of the leading companies making their mark within the immuno-oncology theme are Novartis Merck & Co., Gilead Sciences, Roche, Bristol Myers Squibb, AstraZeneca, IQVIA, and Sanofi among others.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Still undecided about purchasing this report?
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.